Rituximab exhibits a better safety profile when used as a first line of treatment for pemphigus vulgaris: a retrospective study

Z Aryanian, K Balighi, M Daneshpazhooh… - International …, 2021 - Elsevier
Background Pemphigus is an autoimmune disease that is challenging to treat and has few
available therapeutic options. Recently, several studies have demonstrated that rituximab …
被引用次数：46 相关文章

[引用][C] Rituximab exhibits a better safety profile when used as a first line of treatment for pemphigus vulgaris: A retrospective study

Z Aryanian, K Balighi, M Daneshpazhooh… - International …, 2021 - cir.nii.ac.jp
Rituximab exhibits a better safety profile when used as a first line of treatment for pemphigus
vulgaris: A retrospective study | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ …

Rituximab exhibits a better safety profile when used as a first line of treatment for pemphigus vulgaris: A retrospective study.

Z Aryanian, K Balighi, M Daneshpazhooh… - International …, 2021 - europepmc.org
Background Pemphigus is an autoimmune disease that is challenging to treat and has few
available therapeutic options. Recently, several studies have demonstrated that rituximab …

Rituximab exhibits a better safety profile when used as a first line of treatment for pemphigus vulgaris: A retrospective study

Z Aryanian, K Balighi… - International …, 2021 - pubmed.ncbi.nlm.nih.gov
Background Pemphigus is an autoimmune disease that is challenging to treat and has few
available therapeutic options. Recently, several studies have demonstrated that rituximab …